Previous 10 | Next 10 |
Pulse Biosciences, Inc . (NASDAQ:PLSE), a bioelectric medicine technology company bringing to market its proprietary CellFX™ System, today announced its patented Nano-Pulse Stimulation™ (NPS™) technology will be featured in a series of podium presentations in the “...
Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System announced today that the Company will report second quarter 2019 operational highlights and ...
Gainers: ARCA biopharma (NASDAQ: ABIO ) +37% . MFC Bancorp (NYSE: MFCB ) +32% . Enphase Energy (NASDAQ: ENPH ) +29% . Precipio (NASDAQ: PRPO ) +25% . Nu Skin Enterprises (NYSE: NUS ) +25% . Nanometrics Incorporated (NASDAQ: NANO ) +22% . Qumu Corporation (NASDAQ: QUMU ) +22% ....
Thinly traded micro cap Pulse Biosciences ( PLSE -20.3% ) slumps on almost double normal volume, albeit on turnover of only 120K shares, in response to its disclosure that the FDA has requested additional information related to the 510(k) application for its CellFX System used in derma...
Pulse Biosciences, Inc. (PLSE) Q1 2019 Earnings Conference Call April 30, 2019 4:30 PM ET Company Participants Brian Dow – Senior Vice President and Chief Financial Officer Darrin Uecker – President and Chief Executive Officer Ed Ebbers – Vice President and G...
Pulse Biosciences (NASDAQ: PLSE ): Q1 GAAP EPS of -$0.49 misses by $0.05. More news on: Pulse Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
We've seen this movie before. A biotech falls flat on its face, its flagship drug getting rejected by the FDA just in time for a financial crisis. Bob Duggan takes over in the middle of the crisis, pours money into the company, and sells it seven years later for $21 billion. This was the s...
Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System today announced that the Company will report first quarter 2019 operational highlights and financial results on Tuesday, April 30, 2019. Pulse Biosciences managemen...
Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced that key findings from its clinical programs using Nano-Pulse Stimulation™ (NPS™) technology will be presented at the American Societ...
The following slide deck was published by Pulse Biosciences, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Pulse Biosciences Inc Company Name:
PLSE Stock Symbol:
NASDAQ Market:
Pulse Biosciences Inc Website:
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the second quarter 2024 after market close on Monday, August 12, 2024. Company managemen...
2024-07-15 17:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...